A consideration may be that modulation of hepatic de novo lipogenesis via the SREBP-1c and DGAT-2 pathways by Jiangzhi Capsule is insufficient to improve fructose-induced hypertriglyceridemia. The gene discussed is DGAT2; the disease is hypertriglyceridemia.